At any given moment, the FDA is in the process of approving a new targeted cancer therapy or new indications for existing targeted therapies. More than 25 new targeted therapies were approved by the FDA last year, making it more complicated to track approved indications by new targeted therapies. Meanwhile, clinical trials continuously add to the already massive mountains of critical scientific data.
KEW keeps track of all of it. And CANCERPLEX applies it to each individual patient.
In typically 3 – 5 pages, the report reveals any therapies relevant to your patient’s cancer while eliminating less effective therapies. To further simplify the process, our pathologists summarize the most important information for the treating physician on the first page.Learn more about CANCERPLEX